Trials / Completed
CompletedNCT02558504
Radiofrequency in the Treatment of Barrett's Oesophagus
Clinical and Medico-economic Evaluation of Radiofrequency Ablation Versus Oesophagectomy in the Treatment of High Grade Dysplasia in Barrett's Oesophagus
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 87 (actual)
- Sponsor
- Hospices Civils de Lyon · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
First intent treatment for superficial circular esophageal neoplasm is surgical resection. Endoscopic mucosal resection is not recommended due to the high rate of subsequent esophageal stenosis (higher than 80%). Surgical limits are related to a high level of morbidity due, in particular, to respiratory complications or infections that require prolonged hospitalisations, and by significant rate of mortality (from 2 to 5 %). As an alternative to the surgical treatment, an innovative technique to remove esophageal circular preneoplastic and neoplastic lesions has been developed: it consists to ablate the mucosa by means of a balloon of a fixed diameter which incorporates approximately 100 electrodes on its surface that emit radiofrequency waves (HALO® Radiofrequency Ablation Technology System). By varying the strength and the duration of the electrical impulses, it is possible to obtain a homogenous and controlled destruction of the tissue of the whole mucosa, leaving no remaining pre-neoplastic or neoplastic elements underneath. The technique will be used for high grade glandular epithelial neoplasia, Vienna 4-1 or 4-2, developed on a mucosa at risk, i.e. the Barrett's oesophagus, occupying more than half of the circumference of the esophagus and that requires surgical treatment. The expected benefit for the patient is linked to the reduced invasiveness of the technique in comparison to the surgery
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Oesophagectomy | |
| DEVICE | Radiofrequency ablation |
Timeline
- Start date
- 2013-01-07
- Primary completion
- 2021-01-18
- Completion
- 2021-01-18
- First posted
- 2015-09-24
- Last updated
- 2025-10-02
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT02558504. Inclusion in this directory is not an endorsement.